The global Allergy Diagnostics Market was valued at USD 4.91 billion in 2023 and is projected to reach USD 13.68 billion by 2032, with a CAGR of 12.06%. Factors driving growth include increased allergies, early diagnosis awareness, and advanced diagnostic devices. The US is the largest market due to healthcare infrastructure and diagnostic testing acceptance.

Consumables dominated the market in 2023, driven by the increasing prevalence of allergies worldwide. In vitro testing was the leading segment, with high specificity and predictive value. Inhaled allergens accounted for the majority in 2023 due to high respiratory allergy incidence. Hospital-based labs and clinics had the highest market share in 2023.

North America led the market in 2023 with 38.21% of revenue, due to robust healthcare infrastructure and insurance coverage. Asia Pacific is expected to have the fastest growth, driven by rising healthcare expenditure and awareness. Recent developments include new allergy testing platforms, AI-driven analytics, and rapid home testing solutions.

Major players in the market include Thermo Fisher Scientific, DASIT Group, AESKU.GROUP GmbH, Astellas Pharma, Epigenomics AG, Sun Pharmaceutical, and Teva Pharmaceutical. The market is expected to grow further with increased R&D investments and new clinical applications. Our company is committed to providing clients with up-to-date market data, consumer insights, and opinions through various research methods such as surveys, video talks, and focus groups globally. The goal is to equip clients with the knowledge they need to navigate changing circumstances and make informed decisions with confidence.

Read more at GlobeNewswire: Allergy Diagnostics Market Set to Reach USD 13.68 Billion